Bridgefront Capital’s Fulgent Genetics FLGT Stock Holding History

Bridgefront Capital’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,559	Closed	-$440K	–	698
2021 Q1	$440K	Buy	+4,559	New	+$471K	0.14%	279

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bridgefront Capital's FLGT Position: Q2 2021 in Review

Bridgefront Capital sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 4,559 shares — an estimated $440K sold.

Bridgefront Capital first reported a position in FLGT in Q1 2021 and held it in 1 quarter. The position peaked at $440K in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

Bridgefront Capital reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
Bridgefront Capital sold 4,559 Fulgent Genetics shares in Q2 2021, an estimated $440K.
Bridgefront Capital first reported a position in Fulgent Genetics in Q1 2021 and held it in 1 quarter.
Bridgefront Capital's Fulgent Genetics position peaked at $440K in Q1 2021.
254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.